Oddo BHF raises target for Novo Nordisk stock from DKK 221 to DKK 305

Published on 10/27/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 adjusted sales rose 7.00 percent to DKK 78.49 billion at CER. Novo Nordisk stock costs EUR 34.86 on October 27, 2026, down 0.06 percent from EUR 34.88.

Analyst target and quarterly sales

Oddo BHF lifted its target from DKK 221 to DKK 305 on October 20, 2026.
Adjusted second-quarter sales reached DKK 78.49 billion, up 7.00 percent at constant exchange rates.
Novo Nordisk stock trades at EUR 34.86 at 10:38 a.m. CEST at Lang & Schwarz on October 27, 2026, 0.06 percent below the Xetra close of October 26, 2026.

Novo-Nordisk, DK0062498333, Illustration mit AI erstellt.

Novo Nordisk stock trades at EUR 34.86 at Lang & Schwarz on October 27, 2026 at 10:38 a.m. CEST, 0.06 percent below the Xetra close of October 26, 2026 at EUR 34.88. The latest analyst action came from Oddo BHF, which raised its target from DKK 221 to DKK 305 on October 20, 2026, while keeping a Neutral rating, as MarketScreener reported.

Three dated signals shape the stock

The recent chronology links operational progress with a cautious valuation debate. On August 4, 2026, Novo Nordisk reported adjusted second-quarter sales of DKK 78,488 million, up 7.00 percent at constant exchange rates, and adjusted operating profit of DKK 33,389 million, up 11.00 percent, according to GlobeNewswire. On October 15, 2026, the company received an additional Chinese approval for NovoGlic, according to Kapitalmarktexperten. On October 20, 2026, Oddo BHF lifted its target from DKK 221 to DKK 305.

What does 7.00 percent mean?

The sales increase was paired with a more selective profit picture. Novo Nordisk said adjusted operating profit rose 11.00 percent in the second quarter at constant exchange rates, while the report also identified DKK 6.3 billion of non-cash impairment charges tied to intangible pipeline assets. The distinction matters because adjusted growth and reported charges describe different parts of the same period, as the company release explained.

The next reporting date

Novo Nordisk is scheduled to announce results for the first nine months of 2026 on November 4, 2026, according to the company's financial-results calendar published on October 23, 2026 by Novo Nordisk. That release will provide the next reported comparison for sales, operating profit and the company's full-year outlook.

Target raised while price stays near EUR 35

Oddo BHF's higher target did not come with a stronger rating, leaving the analyst action as a valuation adjustment rather than a recommendation change. The upcoming nine-month report will show whether the 7.00 percent adjusted sales increase from the second quarter is carrying into the later period.

Novo Nordisk was trading at EUR 34.86 at Lang & Schwarz on October 27, 2026 at 10:38 a.m. CEST, 0.06 percent below the Xetra close of October 26, 2026 at EUR 34.88. The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.